“While orphan drugs’ share of the $880-billion global pharmaceuticals market remains small—at $50 billion as of the end of 2011, or just 6% of the total—their growth curve has been steep. Thomson Reuters reports that between 2001 and 2010, orphan drugs posted a compound annual growth rate of 25.8%, outstripping the 20.1% CAGR returned by a matched non-orphan control group. With these kinds of eye-popping profits being raked in by orphan drug makers, the investment world has taken notice.”
http://www.caseyresearch.com/cdd/orphans-adding-company-value-in-the-biotech-space
Did you like this?
Tip Freedomwat.ch Staff with Bitcoin
Tip Freedomwat.ch Staff with Bitcoin
Related posts:
The People Say No To War
The European Parliament’s Pro-Tax Politicians Should Go After their Own Tax-Protected Salaries
Bank Of England To The Fed: "No Indication Should, Of Course, Be Given To The Bundesbank..."
Sen. Blumenthal Wants You To Know Train Safety Is Very Important
Pot sales of $5 million in five days and no place to put the money
US Immigration Outlook: From Uncertainty To Panic
Dale Brown of Detroit-based Threat Management Center is On-Point
How Many Pounds of Marijuana Are Being Sold in Colorado A Month?
In USSA, Journalism is a Crime
Jacob Hornberger: The JFK Cover-Up Continues
F-35 Stealth Fighter Is Too Heavy and Slow, So the Pentagon Made Its Performance Tests Easier
No One’s Read the Senate Torture Report and It Might Be Destroyed
Don’t Get Fooled Again — It’s Time to Dump Bonds Now
Ron Paul: For Normal Relations With Cuba, End US Interventionism
UN Shoe Drops on Internet Terror